Genome-wide or exome-wide screening and expanded cfDNA panels that include targets beyond common aneuploidies (trisomies 21, 18, 13) and sex chromosome aneuploidy are considered unproven and not medically necessary. The policy specifically lists genome-wide/exome-wide approaches and expanded panels as excluded from routine coverage, and it notes that current evidence is insufficient to establish clinical utility for broad CNV/microdeletion screening or prenatal exome/genome sequencing. Confirmatory diagnostic testing (e.g., amniocentesis with chromosomal microarray) is recommended when such expanded cfDNA results are reported due to high false-positive rates in the published literature.

Routine use of cfDNA for prenatal exome/genome sequencing, for CNV screening in twin pregnancies, or for broadly screening rare aneuploidies/microdeletions is not supported by current evidence and therefore is excluded from routine coverage. The policy highlights lack of peer-reviewed clinical utility data for these approaches and identifies particularly limited evidence for twin gestations, where no clinical-utility studies were identified.

The American College of Medical Genetics and Genomics (ACMG) states there is insufficient evidence to recommend routine prenatal cfDNA screening for copy number variants (CNVs) other than the 22q11.2 deletion and insufficient evidence to recommend routine screening for rare autosomal trisomies (RATs). ACMG’s guidance therefore does not support routine genome-wide CNV screening by cfDNA outside of targeted or research contexts.

ACOG/SMFM publications note that genome-wide cfDNA screening intended to detect large deletions and duplications and routine microdeletion screening have not been clinically validated and are not recommended. The policy echoes this position, indicating that routine cfDNA microdeletion screening and genome-wide CNV approaches lack sufficient accuracy and validation to support routine clinical use.

UnitedHealthcare considers cfDNA testing using maternal plasma to determine fetal genotype proven and medically necessary only for specific alloimmunization indications; for other expanded indications, cfDNA is regarded as unproven and not medically necessary. The policy revision clarifies that testing beyond standard aneuploidy screening—including expanded panels, genome- or exome-wide analyses, microdeletion/CNV screens, and most single-gene screenings—are not supported for routine coverage.

Cell-free fetal DNA testing using maternal plasma is considered unproven and not medically necessary for indications beyond screening for trisomies 21, 18, 13, and sex chromosome aneuploidy. Examples of excluded routine uses include single-gene population screening, fetal antigen testing other than RhD, and testing solely to determine twin zygosity.

Additional indications listed as unproven or not medically necessary include genome-wide/exome-wide screening, expanded cfDNA panels beyond common trisomies and sex chromosome aneuploidy, microdeletions/microduplications/CNV screening, and single-gene disorder screening. The Instructions for Use section explicitly enumerates these as examples of applications that lack sufficient evidence to support routine coverage.

Use of cfDNA testing to evaluate single-gene disorders remains in early development with limited evidence from small studies. ACOG has stated there is insufficient evidence to support single-gene cfDNA screening for general-population use, and the policy lists single-gene NIPT approaches among indications considered unproven or not medically necessary pending further validation.

Routine single-gene cfDNA screening and unvalidated genome-wide CNV/microdeletion cfDNA screening are not supported by sufficient evidence for general population use. The policy therefore does not endorse these approaches for routine coverage and identifies them among not medically necessary indications.

Cell-Free Fetal DNA expanded panel testing—that is, panels that include targets beyond trisomies 21, 18, 13, and sex chromosome aneuploidy—is specifically listed as limited/not covered. This revision clarifies that expanded panel testing and other previously listed expanded uses are considered unproven and not medically necessary for routine screening.

The policy’s not-covered list includes genome-wide or exome-wide screening, expanded cfDNA panels beyond trisomies 21/18/13 and sex chromosome aneuploidy, microdeletions/CNV screening, and single-gene NIPD where evidence is insufficient. Expanded panel testing beyond common trisomies and SCA is explicitly added to the revised not medically necessary items.

Routine cfDNA use for prenatal exome/genome sequencing and broad microdeletion/CNV screening without a clear, evidence-based indication is not supported by current data and is included among indications not covered by this policy. The policy notes the absence of peer-reviewed clinical-utility studies for these applications.

Routine screening for CNVs other than 22q11.2 deletions and routine screening for rare autosomal trisomies (RATs) are not supported by sufficient evidence; ACMG and ACOG/SMFM guidance cite lack of validation and low/variable positive predictive values for these uses, and the policy therefore excludes routine coverage.

Additional not-covered items summarize that cfDNA applications beyond standard trisomy and sex chromosome screening are considered unproven. The policy revision consolidates these expanded uses into the not medically necessary category to align coverage with current evidence.

Expanded panel testing beyond trisomies 21, 18, 13, and sex chromosome aneuploidy is specifically listed among revised not medically necessary items. The policy history documents this change and the removal or replacement of other previously listed expanded uses to reflect current evidence-based exclusions.

Eligibility for RhD/fetal genotype testing in alloimmunized or at-risk pregnancies requires documentation that the pregnant individual is alloimmunized or at risk, and that paternal genotyping shows heterozygosity for RhD or paternal RhD status is unknown; the policy revision also requires that indicated invasive diagnostic testing be offered and declined.

Family history criteria are not detailed for most cfDNA indications in the provided text. For single-gene NIPD (e.g., RHDO) and targeted approaches, prior molecular diagnosis in the family and reference samples may be required for assay design and interpretation, but these requirements are not enumerated as general eligibility criteria for screening cfDNA tests.

For single-gene NIPD approaches, prior molecular diagnosis in an affected family member and the availability of reference samples for phasing may be necessary to design and validate the assay; the policy notes these are procedure-specific requirements rather than broad eligibility criteria.

The policy indicates documentation should support alloimmunization status or risk, paternal genotyping results, and that invasive diagnostic testing was offered and declined when fetal genotype determination is being requested for alloimmunized or at-risk pregnancies; for RHDO-based or single-gene NIPD, prior molecular diagnosis and reference samples may be required for testing to proceed.

Reference the policy revision history for recent changes affecting eligibility and coverage language, including added requirements for paternal genotyping status and documentation when fetal genotype testing is requested for alloimmunized or at-risk pregnancies.

Cell-free fetal DNA (cfDNA) circulating in maternal blood can be analyzed noninvasively starting in the first trimester (commonly available at 10+ weeks gestation) to screen for common fetal aneuploidies. cfDNA is a screening test, not diagnostic; screen-positive or inconclusive results should prompt genetic counseling and offer of confirmatory invasive diagnostic testing (e.g., CVS or amniocentesis with chromosomal microarray).

This policy was revised to add coverage language for cfDNA RhD genotyping in alloimmunized pregnancies with specific documentation requirements and to mark expanded panel testing beyond trisomies and sex chromosome aneuploidy as not medically necessary.

The not-covered list was revised to add explicit reference to Cell-Free Fetal DNA expanded panel testing (panels that include testing beyond trisomies 21, 18, 13, and sex chromosome aneuploidy) as a revised not medically necessary item.